礼新医药 is a biopharmaceutical company based in China that focuses on the research and development of innovative drugs in the fields of tumor immunotherapy and tumor microenvironment. It develops large molecule antibodies and antibody-drug conjugates, and has various projects advancing into clinical research.

礼新医药

LaNova Medicines | 164 followers on LinkedIn. Care for life. Dedicate to innovation. | Founded in 2019 in Shanghai, China, LaNova Medicines is a clinical-stage biotechnology company committed to the discovery and development of novel biologic drugs for cancer treatment.

Led by industry veterans with a strong passion for innovation, we aim to operate as an R&amp;D engine and deliver transformative medicines to address the unmet clinical needs of cancer patients. Leveraging our proprietary technology platforms and deep understanding of the tumor microenvironment. we have built a differentiated pipeline of products and are striving to progress our programs toward the clinic.

LaNova Medicines Ltd. - Chief Operating Officer

Jason Li

LaNova Medicines - Sr.Director of Discovery

Wentao Huang

Director, Medical Sciences

Da Fei

LaNova Medicines - Medical Science VP

Sherry Qin

LaNova Medicines

msh id	COM:LANOVAMEDICINES
symbol	-
name	礼新医药
homepage url	https://www.lanovamedicines.com
country	CN
sector	Healthcare & Health Services
industry	Pharmaceuticals
market	PRIVATE
employee count	-
crunchbase url	https://www.crunchbase.com/organization/lanova-medicines
linkedin url	https://www.linkedin.com/company/lanova-medicines
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

LANO

COM:LANOVAMEDICINES

礼新医药

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-